Company profileNeural interface
INBRAIN Neuroelectronics
Graphene-based cortical interfaces for high-resolution recording and stimulation.
- Location
- Barcelona, Spain
- Founded
- 2019
- Class
- Neural interfaceGraphene electrode arrays aimed at closed-loop therapy; human use so far is intraoperative mapping.Not counted among core BCI companies.
- Website
- inbrain-neuroelectronics.com
- Funding stage
- Series B
- Sources last checked
- 6 Oct 2026
What they are building
Develops graphene electrode arrays that the company gives as 10 micrometres thick, intended for brain mapping and closed-loop therapy. Their first use in people was during tumour surgery at Salford Royal Hospital in Manchester.
- Interface category
- Electrocorticography · ECoG, recording and stimulating
- Signal
- ECoG: Local field potentials, including high-gamma activityECoG + stim: Field potentials out; electrical pulses in
- Invasiveness
- Invasive
- Recording / stimulation
- Recording and stimulation
- Device
- Graphene cortical interface — Thin-film graphene electrode array on the cortical surface
- Regulatory status
- Investigational; first-in-human study completed
- Main use cases
- Restore, Monitor
- Works with
- University of Manchester / Northern Care Alliance
Where they are clinically
First-in-human
The first use of a device in a small number of people, focused on safety.
Access today
Experimental human research
Demonstrated in a small number of research participants. Not an established treatment.
- Shown in people
- Graphene electrodes used for brain mapping during surgery in ten participants. The first-in-human study was completed in June 2026 and has not been published.
- Still an aim
- Closed-loop therapy from a chronically implanted graphene array.
- What stands in the way
- Chronic evidence: whether graphene keeps its electrical advantage inside the body over years.
On record here: 1 registered study · 10 participants planned or enrolled · 0 peer-reviewed papers
This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.
Why this company matters
INBRAIN is a materials bet: that graphene's charge-injection and thinness translate into better stimulation and recording at small contact sizes. A completed ten-participant first-in-human study is a meaningful step; published results will show whether the material advantage holds in people.
Key milestones
24 Jun 2026
First-in-human study completes with ten participants.
First-in-human clinical investigation of graphene electrodes for brain mapping · NCT06368310
29 Oct 2024
Series B of $50M led by imec.xpand. The release also states an FDA Breakthrough Device designation for Parkinson's disease.
6 Aug 2024
First-in-human investigation of graphene electrodes for brain mapping begins in Manchester.
First-in-human clinical investigation of graphene electrodes for brain mapping · NCT06368310
Clinical programmes
- First-in-human clinical investigation of graphene electrodes for brain mapping
Intraoperative use of graphene electrodes in ten participants.
First-in-humanCompleted
10 actualNCT06368310
Funding history
- 29 Oct 2024$50MSeries B · led by imec.xpand
Investors namedimec.xpand
Rounds in the Briefing’s sample only; not a complete funding history.
IP and patents
Filings touch 5 of the 11 layers, most often interface and electrodes (11 of 12 families) and stimulation (9).
- 12
- patent families identified and counted as BCI
- 2020
- earliest first filing among them
- 11
- first filed since 2021; the latest years are incomplete
- 5 of 12
- include a granted member, of those whose family record was read
Across the stack: families by layer
Themes, by number of families: electrodes and arrays (11), stimulation (9), peripheral interfaces (7), materials and coatings (4), packaging and hermeticity (4), wireless telemetry (4). A family can carry several.
Published in: United States (8), China (5), Spain (4), Japan (4), Brazil (1), counted over the 12 families whose full record was read.
Representative families
- Neuromodulation systemfirst filed 2023 · Electrodes and arrays, Peripheral interfaces, Implant electronicsApplication
- Neural interface with edge protected porous materialfirst filed 2021 · Electrodes and arrays, Peripheral interfaces, Packaging and hermeticityGranted · EP
- Medical electrode and arrangement thereoffirst filed 2021 · Electrodes and arrays, Peripheral interfacesGranted · EP, US
- Neurostimulation systemfirst filed 2021 · Electrodes and arrays, Materials and coatings, Implant electronicsGranted · EP, US
- Electrochemically activated and reduced graphene oxide structurefirst filed 2021 · Electrodes and arrays, Materials and coatings, Peripheral interfacesGranted · EP, US
- Flexible electrode carrierfirst filed 2020 · Electrodes and arrays, Peripheral interfaces, Packaging and hermeticityGranted · EP
6 more families counted
- System for transferring a thin film and method thereoffirst filed 2025 · Electrodes and arraysApplication
- Electrode modulefirst filed 2024 · Electrodes and arrays, Materials and coatings, Peripheral interfacesApplication
- Neural interface and closed-loop decoding and neuromodulation/neurostimulation system including the samefirst filed 2023 · Electrodes and arrays, Neural decoding, StimulationApplication
- Protective casing for a thin-film lead paddlefirst filed 2022 · Electrodes and arrays, Packaging and hermeticity, Connectors and feedthroughsApplication
- Neurostimulation systemfirst filed 2021 · Electrodes and arrays, Materials and coatings, Peripheral interfacesApplication
- Neuromodulation device programming optimizing method and systemfirst filed 2021 · Wireless telemetry, Stimulation, Closed loopApplication
Families found for INBRAIN Neuroelectronics in the EPO’s worldwide database, grouped so that one invention counts once. A filing shows what a company sought to protect. It does not show that the technology was built, is in a product, or works in people, and themes are read from titles, abstracts and classes, not from the claims. How to read this
Competitive context
Sources
- 01
Company reportedimec (press release)29 Oct 2024Checked against source 6 Oct 2026
A release carried by the parent of the round's lead investor. It states the round, the first human use at Salford Royal Hospital in Manchester, the 10-micrometre thickness and an FDA Breakthrough Device designation for Parkinson's disease.
- 02
ClinicalTrials.gov NCT06368310 (opens in a new tab)
Clinical registryClinicalTrials.gov30 Jun 2026Checked against source 3 Oct 2026
Registry record last updated 2026-06-30.